Please login to the form below

Not currently logged in
Email:
Password:

Xceleron and Organon sign microdose study agreement

Xceleron collaborates with Organon on a three-compound human microdose study focusing on candidate selection for further clinical development

UK-based contract research organisation Xceleron has revealed a collaboration with Organon, the human healthcare business unit of Netherlands-based Akzo Nobel, on a three-compound human microdose study focusing on candidate selection for further clinical development.

The three selected drug candidates are all compounds from Organon' gynaecological R&D activities. The purpose of the human microdose study is to assess all important pharmacokinetic properties of the compounds, while confirming the scalability of the microdose to pharmacological dose for these compounds.

Xceleron will use its Accelerator Mass Spectrometry analytical technology to determine human plasma concentrations after microgram administration of the various drug candidates.

Xceleron' founder and CEO Professor Colin Garner said: "We are delighted that Organon has further demonstrated its willingness to adopt innovative approaches to drug development and are proud to add them to Xceleron' rapidly growing, international portfolio of human microdose supporters."

30th September 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
EY Life Sciences

Our global reach Against a backdrop of regulatory, digital, financial and global transformation, Life Sciences companies are finding integration and...

Latest intelligence

How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...
Medopad: the up and coming unicorn transforming remote patient monitoring
Blue Latitude Health speaks to Medopad’s Martha Carruthers to learn how the start-up’s modular apps are helping patients with complex diseases....

Infographics